摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-butylcyclohexanecarbonyl chloride | 67679-84-9

中文名称
——
中文别名
——
英文名称
4-butylcyclohexanecarbonyl chloride
英文别名
trans-4-n-butylcyclohexane carboxylic acid chloride;4-n-butyl-cyclohexanecarboxylic acid chloride;4-Butylcyclohexane-1-carbonyl chloride
4-butylcyclohexanecarbonyl chloride化学式
CAS
67679-84-9
化学式
C11H19ClO
mdl
——
分子量
202.724
InChiKey
ZHJCVLQOKPGYDJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.7
  • 重原子数:
    13
  • 可旋转键数:
    4
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.91
  • 拓扑面积:
    17.1
  • 氢给体数:
    0
  • 氢受体数:
    1

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Method of making and using 7α, 11β-dimethyl-17β-hydroxyestr-4-en-3-one 17-undecanoate
    申请人:Blye Richard P.
    公开号:US10351587B2
    公开(公告)日:2019-07-16
    Methods of using 7α,11β-dimethyl-17β-hydroxy-4-estren-3-one bucyclate (I) and 7α,11β-dimethyl-17β-hydroxyestr-4-en-3-one 17-undecanoate (II) for various hormonal therapies, dosage forms comprising 7α,11β-dimethyl-17β-hydroxy-4-estren-3-one bucyclate and 7α,11β-dimethyl-17β-hydroxyestr-4-en-3-one 17-undecanoate, and processes for their preparation.
    使用7α,11β-二甲基-17β-羟基-4-雌甾-3-酮丁酸酯(I)和7α,11β-二甲基-17β-羟基雌甾-4-烯-3-酮-17-十一烷酸酯(II)进行各种激素疗法的方法,包括7α,11β-二甲基-17β-羟基-4-雌甾-3-酮丁酸酯和7α,11β-二甲基-17β-羟基雌甾-4-烯-3-酮-17-十一烷酸酯的剂型,以及它们的制备方法。
  • Liquid crystal substituted trans-4-n-alkylcyclohexanes and
    申请人:——
    公开号:US04490278A1
    公开(公告)日:1984-12-25
    The invention relates to liquid crystal nematic substances for electro-optical devices for the modulation of light, for the reproduction of numerals, signs and images as well as an orienting medium for spectroscopy and gas chromatography. It was found that compounds containing two or three rings, connected by carboxyl groups are new liquid crystal nematic substances of the general formula ##STR1## where R.sup.1 =C.sub.n H.sub.2n+1, CN; R.sup.2 =C.sub.m H.sub.2m+1, CN;R.sup.3 =H, CH.sub.3, C.sub.2 H.sub.5 Cl, Br; x=0 or 1; m,n=numbers from 1 to 10 are suitable for electro-optical arrangements for the modulation of transmitted or reflected light as well as for the reproduction of numeral signals and images, and further, as an orienting medium for spectroscopy and gas chromotography. Other liquid crystal substances or non-liquid crystalline substances, particularly dyes, may be added to the substances according to the invention.
    该发明涉及用于电光装置的液晶向列相物质,用于光的调制,用于数字、标志和图像的再现,以及用作光谱学和气相色谱的取向介质。发现含有两个或三个环,通过羧基连接的化合物是一种新的液晶向列相物质,其一般式为##STR1##其中R.sup.1 =C.sub.n H.sub.2n+1, CN; R.sup.2 =C.sub.m H.sub.2m+1, CN; R.sup.3 =H, CH.sub.3, C.sub.2 H.sub.5 Cl, Br; x=0或1; m,n=从1到10的数字适用于用于电光排列的调制透射或反射光以及数字信号和图像的再现,还可用作光谱学和气相色谱的取向介质。其他液晶物质或非液晶物质,特别是染料,可以添加到该发明的物质中。
  • COMPOUNDS FOR THE TREATMENT OF SEIZURES AND OTHER CENTRAL NERVOUS SYSTEM DISORDERS AND CONDITIONS
    申请人:Ketogen Inc.
    公开号:US20150344413A1
    公开(公告)日:2015-12-03
    The present application relates to novel compounds comprising a moiety that leads to the metabolic production of ketones bonded to a ketone-potentiated anti-epileptic drug, compositions comprising these compounds, and their use, for example for the treatment of epilepsy, and other CNS diseases, disorders or conditions. In particular, the present application includes compounds of Formula I, and compositions and uses thereof:
    本申请涉及包含导致产生酮类代谢产物的基团与酮增强型抗癫痫药物结合的新化合物,包括这些化合物的组合物,以及它们的用途,例如用于治疗癫痫和其他中枢神经系统疾病、障碍或状况。具体来说,本申请包括Formula I的化合物、组合物及其用途:
  • Liquid crystalline substances
    申请人:VEB Werk fuer Fernsehelektronik
    公开号:US04626375A1
    公开(公告)日:1986-12-02
    New liquid-crystalline esters of the 4-[(4-alkyl-cyclohexyl)-methyl]-benzoic acids or cyclohexanecarboxylic acids which are suitable for electro-optical displays have the general formula ##STR1## wherein R.sup.1 =C.sub.n H.sub.2n+1 R.sup.2 =H, ##STR2## wherein n=an integer from 1 to 10, m=an integer from 1 to 10, S=an integer from 1 to 10. The aforementioned esters are produced by converting the corresponding 4-alkylcyclohexanecarboxylic acid chloride according to Friedel-Crafts with benzene, reduction of the corresponding ketones to 4-alkyl-cyclohexyl-methyl-benzene, Friedel-Crafts acylation with acetyl chloride and oxidation with bromine to the 4-[(4-alkyl-cyclohexyl)-methyl]-benzoic acids, which are esterified according to conventional methods with substituted cyclohexanols or phenols or are hydrogenated with hydrogen and Raney-Nickel under high-pressure to 4-[(4-alkyl-cyclohexyl)-methyl]-cyclohexanecarboxylic acids, and then are esterified according to conventional procedures with substituted cyclohexanols or phenols.
    4-[(4-烷基-环己基)-甲基]-苯甲酸或环己基甲酸的新液晶酯适用于电光显示,其具有以下一般式:##STR1## 其中R.sup.1=C.sub.n H.sub.2n+1,R.sup.2=H,##STR2## 其中n为1至10的整数,m为1至10的整数,S为1至10的整数。上述酯类是通过将相应的4-烷基环己基甲酸氯化物按照Friedel-Crafts法与苯反应,将相应的酮还原为4-烷基环己基甲基苯,然后进行Friedel-Crafts酰化反应,使用乙酰氯和溴氧化成4-[(4-烷基-环己基)-甲基]-苯甲酸,然后按照常规方法用取代环己醇或酚酯化或在高压下使用氢和Raney-Nickel还原成4-[(4-烷基-环己基)-甲基]-环己基甲酸,然后按照常规程序用取代环己醇或酚酯化。
  • [EN] CYCLOALKYL-CARBOXYLIC ACID ESTERS OF 7.ALPHA.METHYL-ESTR-4-EN-3-ONE 17.BETA.-OL (19-NOR 7.ALPHA.-METHYLTESTOSTERONE)<br/>[FR] ESTERS D'ACIDE CYCLOALKYL-CARBOXYLIQUE DE 7.ALPHA.METHYL-ESTR-4-EN-3-ONE 17.BETA.-OL (19-NOR 7.ALPHA-METHYLTESTOSTERONE)
    申请人:AKZO NOBEL N.V.
    公开号:WO1999067270A1
    公开(公告)日:1999-12-29
    (EN) The invention is the novel androgen (7$g(a),17$g(b))-17-[[($i(trans)-4-butylcyclohexyl)carbonyl]oxy]-7-methylestr-4-en-3-one (MENT buciclate) and related cycloalkyl esters. This compound distinguishes favourably from other testosterone derivatives in that it has a good solubility in oily media. It particularly exhibits a good dissolved potency relative to testosterone. The compound is particularly suitable for administration by means of injection.(FR) L'invention concerne un nouvel androgène (7$g(a),17$g(b))-17-[[($i(trans)-4-butylcyclohexyl)carbonyl]oxy]-7méthylestr-4-en-3-one (buciclate de 7$g(a)-méthyl-19-nortestostérone -MENT-) et des esters de cycloalkyle associés. Ce composé se distingue favorablement des autres dérivés testostérone en ce qu'il possède une bonne solubilité dans des milieux huileux, et en ce qu'il démontre notamment un bon pouvoir de dissolution par rapport à la testostérone. Ce composé est spécialement conçu pour être administré par injection.
    这项发明涉及一种新型雄激素(7α,17β)-17-[[($i(trans)-4-丁基环己基)甲酰基]氧基]-7-甲基麦角甾-4-烯-3-酮(7α-甲基-19-去甲睾酮丁酸酯-MENT)和相关的环烷基酯。该化合物相对于其他睾酮衍生物具有良好的油性介质溶解度,尤其表现出良好的溶解效力。该化合物特别适合通过注射途径给药。
查看更多